These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24045678)

  • 1. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
    Simon JA; Portman DJ; Kaunitz AM; Mekonnen H; Kazempour K; Bhaskar S; Lippman J
    Menopause; 2013 Oct; 20(10):1027-35. PubMed ID: 24045678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.
    Pinkerton JV; Joffe H; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
    Menopause; 2015 Jan; 22(1):50-8. PubMed ID: 25137243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
    Stearns V; Beebe KL; Iyengar M; Dube E
    JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
    Portman DJ; Kaunitz AM; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
    Menopause; 2014 Oct; 21(10):1082-90. PubMed ID: 24552977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials.
    Riemma G; Schiattarella A; La Verde M; Zarobbi G; Garzon S; Cucinella G; Calagna G; Labriola D; De Franciscis P
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31480427
    [No Abstract]   [Full Text] [Related]  

  • 6. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine.
    Simon JA; Chandler J; Gottesdiener K; Lazarus N; He W; Rosenberg E; Wagner JA; Denker AE
    Menopause; 2014 Sep; 21(9):938-44. PubMed ID: 24569618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis.
    Wei D; Chen Y; Wu C; Wu Q; Yao L; Wang Q; Wang XQ; Yang KH
    BJOG; 2016 Oct; 123(11):1735-43. PubMed ID: 27062457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
    Capriglione S; Plotti F; Montera R; Luvero D; Lopez S; Scaletta G; Aloisi A; Serra GB; Angioli R
    Gynecol Oncol; 2016 Dec; 143(3):584-588. PubMed ID: 27751589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
    Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation.
    Soares CN; Joffe H; Viguera AC; Petrillo L; Rydzewski M; Yehezkel R; Somley B; Cohen LS
    Am J Med; 2008 Feb; 121(2):159-162.e1. PubMed ID: 18261506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
    Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
    Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.
    Takamatsu K; Miki T; Miyazaki K; Hashimoto A; He W; Wang X
    Climacteric; 2024 Aug; 27(4):389-397. PubMed ID: 38864290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
    Stearns V; Slack R; Greep N; Henry-Tilman R; Osborne M; Bunnell C; Ullmer L; Gallagher A; Cullen J; Gehan E; Hayes DF; Isaacs C
    J Clin Oncol; 2005 Oct; 23(28):6919-30. PubMed ID: 16192581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
    Montgomery SA; Kennedy SH; Burrows GD; Lejoyeux M; Hindmarch I
    Int Clin Psychopharmacol; 2004 Sep; 19(5):271-80. PubMed ID: 15289700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.